Related Experiment Videos
Spiramycin: in-vitro activity on Branhamella catarrhalis
1Unité d'Ecologie Bactérienne, Institut Pasteur, Paris, France.
The Journal of Antimicrobial Chemotherapy
|July 1, 1988
Summary
This study assessed spiramycin susceptibility in Branhamella catarrhalis bacteria. Over 97% of strains showed susceptibility, indicating spiramycin remains effective against this pathogen.
Area of Science:
- Microbiology
- Infectious Diseases
- Pharmacology
Background:
- Branhamella catarrhalis is a significant respiratory pathogen.
- Antibiotic resistance in B. catarrhalis necessitates ongoing surveillance.
- Macrolide antibiotics like spiramycin are used to treat bacterial infections.
Purpose of the Study:
- To evaluate the in-vitro susceptibility of Branhamella catarrhalis strains to spiramycin.
- To determine the Minimum Inhibitory Concentrations (MICs) for spiramycin against B. catarrhalis.
- To assess if penicillinase production affects spiramycin susceptibility.
Main Methods:
- Collected 103 strains of Branhamella catarrhalis isolated between 1982 and 1987.
- Determined the Minimum Inhibitory Concentrations (MICs) of spiramycin for each strain.
- Compared susceptibility between penicillinase-producing and non-producing strains.
Main Results:
- Over 97% of B. catarrhalis strains exhibited susceptibility to spiramycin (MIC ≤ 8 mg/l).
- Only two strains showed MICs greater than 8 mg/l, with one strain having an MIC of 16 mg/l.
- No significant difference in spiramycin susceptibility was observed between penicillinase-producing and non-producing strains.
Conclusions:
- Spiramycin demonstrated high in-vitro activity against Branhamella catarrhalis strains from 1982-1987.
- The findings suggest spiramycin is a potentially effective treatment option for B. catarrhalis infections during this period.
- Penicillinase production does not appear to confer resistance to spiramycin in B. catarrhalis.